Thursday, November 12, 2026

Global Bond Yields Rise in Tandem, Splitting AI Stocks Into Rate Winners and Losers

The US 10-Year Treasury yield is approaching 5% while Japan's equivalent has surged from 2.478 to 2.807, marking a coordinated unwinding of suppressed global borrowing costs. The synchronized rate rise is dividing AI stocks by a single variable: how soon they generate cash. Pre-revenue infrastructure companies face steep valuation cuts; profitable enterprise software firms are holding ground.

LM Salvado
LM Salvado

May 28, 2026

Global Bond Yields Rise in Tandem, Splitting AI Stocks Into Rate Winners and Losers
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

The US 10-Year Treasury yield is approaching 5%, rising from 4.58, while Japan's 10-Year Government Bond yield has jumped from 2.478 to 2.807.1 Together they signal the end of a decade of artificially cheap global capital.

The synchronized rise is cleaving the AI sector along one fault line: cash flow timing.

Higher discount rates compress the present value of distant earnings. Pre-revenue AI infrastructure companies — data center buildouts, chip-dependent compute platforms, model developers projecting 2028 revenue — absorb that compression disproportionately.1 A 40-basis-point increase in the risk-free rate produces a structurally larger haircut when most projected returns sit years away.

Profitable AI enterprise software firms face a different calculus. Microsoft and peers generate near-term cash flows that discount at shorter effective durations.1 Rising rates shrink their valuations less, because less of their intrinsic value depends on distant projections.

Japan's rate move matters beyond Tokyo. For decades, ultra-low Japanese yields made US growth stocks comparatively attractive. As that spread narrows, the relative premium that global capital assigned to American tech equities erodes.1 Investors from Frankfurt to Singapore are recalibrating exposure accordingly.

Rate uncertainty compounds the pressure. The 10-Year US Treasury benchmark oscillated between 4.5 and 4.6 even as the note benchmark pushed toward 5.0, reflecting market disagreement on the terminal rate.1 That dispersion itself is a valuation input — wider uncertainty raises risk premiums across all long-duration assets.

The implied portfolio response is rotation within AI, not exit from it. Reducing weight in unprofitable infrastructure while adding profitable enterprise software with existing contracts represents the rate-resilient position. AI ETF flows over the next 60 days will show whether that rotation is already underway.1

In this story · Knowledge Files

About this analysis

This is a Via News analysis. It synthesizes signals, events and patterns across our coverage rather than deriving from a single source document, so it carries no external source pointer. Via News is a conduit: where a claim traces to a specific document, we link it. How we source

LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com